
## Valeriana Di Castro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3305071/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Endothelin-1 Induces an Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. American Journal of Pathology, 2000, 157, 1703-1711.	1.9	322
2	Role of Endothelin-1 in Neovascularization of Ovarian Carcinoma. American Journal of Pathology, 2000, 157, 1537-1547.	1.9	184
3	Endothelin-1 Induces Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1α in Ovarian Carcinoma Cells. Journal of Biological Chemistry, 2002, 277, 27850-27855.	1.6	182
4	Acquisition of Chemoresistance and EMT Phenotype Is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells. Clinical Cancer Research, 2011, 17, 2350-2360.	3.2	167
5	Endothelin-1 Promotes Epithelial-to-Mesenchymal Transition in Human Ovarian Cancer Cells. Cancer Research, 2005, 65, 11649-11657.	0.4	161
6	β-Arrestin links endothelin A receptor to β-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2806-2811.	3.3	159
7	Endothelin-1 Protects Ovarian Carcinoma Cells against Paclitaxel-Induced Apoptosis: Requirement for Akt Activation. Molecular Pharmacology, 2002, 61, 524-532.	1.0	132
8	Endothelin B Receptor Blockade Inhibits Dynamics of Cell Interactions and Communications in Melanoma Cell Progression. Cancer Research, 2004, 64, 1436-1443.	0.4	115
9	Endothelin-1-induced Prostaglandin E2-EP2, EP4 Signaling Regulates Vascular Endothelial Growth Factor Production and Ovarian Carcinoma Cell Invasion. Journal of Biological Chemistry, 2004, 279, 46700-46705.	1.6	91
10	Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Research, 2003, 63, 2447-53.	0.4	90
11	Endothelin A Receptor/β-Arrestin Signaling to the Wnt Pathway Renders Ovarian Cancer Cells Resistant to Chemotherapy. Cancer Research, 2014, 74, 7453-7464.	0.4	89
12	Endothelin-1 Stimulates Lymphatic Endothelial Cells and Lymphatic Vessels to Grow and Invade. Cancer Research, 2009, 69, 2669-2676.	0.4	87
13	Endothelin-1 and Endothelin-3 Promote Invasive Behavior via Hypoxia-Inducible Factor-1α in Human Melanoma Cells. Cancer Research, 2007, 67, 1725-1734.	0.4	84
14	β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling. Oncogene, 2013, 32, 5066-5077.	2.6	79
15	Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Molecular Cancer Therapeutics, 2006, 5, 833-842.	1.9	74
16	Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Molecular Cancer Therapeutics, 2006, 5, 1483-1492.	1.9	73
17	Combined Targeting of Endothelin A Receptor and Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity. Cancer Research, 2007, 67, 6351-6359.	0.4	65
18	Endothelin-1 Decreases Gap Junctional Intercellular Communication by Inducing Phosphorylation of Connexin 43 in Human Ovarian Carcinoma Cells. Journal of Biological Chemistry, 2003, 278, 41294-41301.	1.6	64

VALERIANA DI CASTRO

#	Article	IF	CITATIONS
19	β-Arrestin 1 is required for endothelin-1-induced NF-κB activation in ovarian cancer cells. Life Sciences, 2014, 118, 179-184.	2.0	64
20	Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells. Clinical Cancer Research, 2004, 10, 4670-4679.	3.2	62
21	ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Molecular Cancer Therapeutics, 2007, 6, 2003-2011.	1.9	61
22	Endothelin Receptor Blockade Inhibits Molecular Effectors of Kaposi's Sarcoma Cell Invasion and Tumor Growth in Vivo. American Journal of Pathology, 2003, 163, 753-762.	1.9	55
23	Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma. Oncogene, 2016, 35, 3432-3442.	2.6	53
24	Endothelin-1 Inhibits Prolyl Hydroxylase Domain 2 to Activate Hypoxia-Inducible Factor-1α in Melanoma Cells. PLoS ONE, 2010, 5, e11241.	1.1	50
25	miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget, 2016, 7, 4009-4023.	0.8	49
26	Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. Journal of Molecular Medicine, 2013, 91, 395-405.	1.7	48
27	The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis, 2014, 35, 840-848.	1.3	44
28	β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer. Nature Communications, 2019, 10, 3196.	5.8	40
29	Endothelin Receptor Blockade Inhibits Proliferation of Kaposi's Sarcoma Cells. American Journal of Pathology, 2001, 158, 841-847.	1.9	34
30	Blocking endothelin-1-receptor/β-catenin circuit sensitizes to chemotherapy in colorectal cancer. Cell Death and Differentiation, 2017, 24, 1811-1820.	5.0	34
31	Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression. Oncotarget, 2016, 7, 17790-17804.	0.8	33
32	Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clinical Science, 2002, 103, 306S-309S.	1.8	31
33	Identification of the ETA Receptor Subtype That Mediates Endothelin-Induced Autocrine Proliferation of Normal Human Keratinocytes. Biochemical and Biophysical Research Communications, 1995, 209, 80-86.	1.0	29
34	β-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinaseThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research Canadian Journal of Physiology and Pharmacology, 2010, 88, 796-801.	0.7	28
35	Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis. Life Sciences, 2016, 159, 43-48.	2.0	25
36	Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clinical Science, 2002, 103, 302S-305S.	1.8	24

#	Article	IF	CITATIONS
37	ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth <i>in vitro</i> . Clinical Science, 2002, 103, 318S-321S.	1.8	21
38	Endothelin-1 Stimulates Cyclooxygenase-2 Expression in Ovarian Cancer Cells Through Multiple Signaling Pathways: Evidence for Involvement of Transactivation of the Epidermal Growth Factor Receptor. Journal of Cardiovascular Pharmacology, 2004, 44, S140-S143.	0.8	20
39	Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cellsThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research Canadian Journal of Physiology and Pharmacology, 2010, 88, 782-787.	0.7	19
40	Endothelin-1 regulates hypoxia-inducible factor-1α and -2α stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells. Life Sciences, 2014, 118, 185-190.	2.0	19
41	Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells. Life Sciences, 2012, 91, 638-643.	2.0	15
42	Endothelin-1/endothelin A receptor axis activates RhoA GTPase in epithelial ovarian cancer. Life Sciences, 2016, 159, 49-54.	2.0	13
43	Endothelin-B Receptor Blockade Inhibits Molecular Effectors of Melanoma Cell Progression. Journal of Cardiovascular Pharmacology, 2004, 44, S136-S139.	0.8	12
44	Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. Cancer Letters, 2020, 492, 84-95.	3.2	12
45	The autonomous growth of human papillomavirus type 16-immortalized keratinocytes is related to the endothelin-1 autocrine loop. Journal of Virology, 1997, 71, 6898-6904.	1.5	12
46	The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis. Life Sciences, 2012, 91, 550-556.	2.0	11
47	Targeting endothelin-1 receptor/β-arrestin1 network for the treatment of ovarian cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 925-932.	1.5	9
48	Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancerThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research Canadian Journal of Physiology and Pharmacology, 2010, 88, 676-681.	0.7	8
49	Therapeutic Targeting of the Endothelin-A Receptor in Human Ovarian Carcinoma: Efficacy of Cytotoxic Agents is Markedly Enhanced by Co-administration with Atrasentan. Journal of Cardiovascular Pharmacology, 2004, 44, S132-S135.	0.8	7
50	Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, 157.	3.5	5
51	168 POSTER Endothelin A receptor/beta-arrestin signaling is critical for ovarian cancer metastasis: novel molecular therapeutic applications. European Journal of Cancer, Supplement, 2008, 6, 54.	2.2	Ο
52	317 Activation of the endothelin signaling pathway is linked with acquisition epithelial–mesenchymal transition phenotype of chemoresistant ovarian cancer cells. European Journal of Cancer, Supplement, 2010, 8, 101.	2.2	0
53	Abstract 698: $\hat{l}^2$ -arrestin-1 as nuclear signalling element essential for endothelin A receptor-induced epithelial to mesenchymal transition and chemoresistance. , 2011, , .		0
54	Abstract 707: Acquisition of chemoresistance and epithelial to mesenchymal phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. , 2011, , .		0

#	Article	IF	CITATIONS
55	Abstract 3086: $\hat{I}$ ±-arrestin-1 acts as a nuclear transcriptional regulator of endothelin A receptor signalling to promote ovarian cancer progression. , 2012, , .		0
56	Abstract 3144: PDZ-RhoGEF/ $\hat{l}^2$ -arrestin-1 interaction mediates endothelin A receptor-induced RhoA activation and cell motility in ovarian tumor cells. , 2014, , .		0
57	Abstract 3580: Downregulated miR-30a promotes acquisition of chemoresistance by targeting endothelin A receptor in ovarian carcinoma. , 2015, , .		Ο
58	Abstract 2901: Nuclear $\hat{l}^2$ -arrestin1 is a critical cofactor of hypoxia-inducible factor-1 $\hat{l}$ ± signaling in endothelin-1-induced ovarian tumor progression. , 2016, , .		0